Revenue increased 203% compared to the three-month period in the prior year Call scheduled for today, May 10 , at 4:30 pm ET TUCSON, Ariz. , May 10, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM) (HTG), a provider of instruments, reagents and services for
The Panel will be available to researchers as part of an early access program TUCSON, Ariz. , May 10, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it will
TUCSON, Ariz. and HUNINGUE, France , May 07, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments, reagents and services for molecular profiling applications, and Firalis S.A. (“Firalis”), a provider of bioanalytical services and biomarker-based
TUCSON, Ariz. , April 27, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it will report its financial results for the quarter ended March 31, 2018 after the market
Mr. Lubniewski assumes the role after having served for seven years as Chief Business Officer TUCSON, Ariz. , April 16, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the
Patent covers nuclease protection methods for detection of nucleotide variants TUCSON, Ariz. , April 03, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the issuance of
TUCSON, Ariz. , March 27, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications today announced that it has entered into a senior debt facility with MidCap Financial (MidCap), a healthcare
Revenue increased 442% and 188%, respectively, compared to the three and twelve month periods in the prior year driven by development efforts supporting Pharma clinical programs TUCSON, Ariz. , March 22, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc.
TUCSON, Ariz. , March 07, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it will report its financial results for the quarter and year ended December 31, 2017 after
Patent covers methods of co-detecting mRNA and small non-coding RNA TUCSON, Ariz. , Feb. 26, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the issuance of Australian
